This is a repository copy of Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/111326/

Version: Supplemental Material

Article:
Diaz, J., Sternberg, C.N., Mehmud, F. et al. (4 more authors) (2016) Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology, 90 (3). pp. 119-126. ISSN 0030-2414

https://doi.org/10.1159/000443647

This is the peer-reviewed but unedited manuscript version of the following article: Diaz J, Sternberg C, N, Mehmud F, Delea T, E, Latimer N, Pandite L, Motzer R, J, Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology 2016;90:119-126. The final, published version is available at http://www.karger.com/?doi=10.1159/000443647

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
### Supplementary Table S1. NICE HTA assessment of pazopanib

#### General information

<table>
<thead>
<tr>
<th><strong>Indication</strong></th>
<th>Pazopanib is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturer</strong></td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td><strong>Type of HTA</strong></td>
<td>Single Technology Appraisal—STA (NICE TA 215)</td>
</tr>
<tr>
<td><strong>Final Guidance (date)</strong></td>
<td>Recommended (February 2011)</td>
</tr>
<tr>
<td><strong>Appraisal Committee</strong></td>
<td>Appraisal Committee C</td>
</tr>
<tr>
<td><strong>Evidence Review/Assessment Group</strong></td>
<td>Aberdeen HTA group</td>
</tr>
</tbody>
</table>

#### Clinical effectiveness—treatment-naive subpopulation

<table>
<thead>
<tr>
<th><strong>Trial comparator</strong></th>
<th>Best supportive care (BSC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sample size (experimental/control)</strong></td>
<td>N = 233 (155/78)</td>
</tr>
</tbody>
</table>
| **Study efficacy outcomes** | Primary endpoint: PFS  
Secondary endpoint: OS |
| **Median PFS** | Pazopanib: 11.1 months  
BSC: 2.8 months (Δ = 8.3 months)  
- HR = 0.40 (95% CI 0.27–0.60) |
| **OS—interim (ITT analysis)** | Pazopanib: NR  
BSC: NR (Δ = NA)  
- HR = 0.74 (95% CI 0.47–1.15) |

BSC = best supportive care; CI = confidence interval; HR = hazard ratio; HTA = health technology assessment; ITT = intent to treat; NA = not available; NR = not reported; NICE = National Institute for Health and Care Excellence; PFS = progression-free survival; OS = overall survival.